Seres Therapeutics reported a fourth‑quarter net loss of $15.3 million, translating to a loss per share of $1.76. Quarterly revenue was $438,000. For the full year, the company posted a net income of $5.7 million on revenue of $0.8 million, a dramatic turnaround from the $125.8 million loss recorded in 2024.
The Q4 loss was largely driven by operating expenses and one‑time charges, but the company’s disciplined cost‑control program helped keep the loss smaller than many analysts had projected. The full‑year profit was enabled by a $5.7 million gain from the sale of its VOWST business to Nestlé Health Science and by significant reductions in research, development and general & administrative costs.
Seres’ cash balance as of December 31, 2025 stood at $45.8 million, including $12.2 million raised through an at‑the‑market equity offering in the fourth quarter. Management indicated that the cash runway should support operations through the third quarter of 2026, but the company is actively pursuing additional financing to fund its clinical pipeline.
The company remains focused on its inflammatory and immunology portfolio. Executive Chair and interim CEO Richard Kender said, "As highlighted in our recent announcements, we are prioritizing our promising inflammatory and immunology biotherapeutics portfolio, including SER‑603 for inflammatory bowel disease." He added, "We are on track to report clinical data from the fully enrolled investigator‑sponsored study at the Memorial Sloan Kettering Cancer Center evaluating SER‑155 to treat immune checkpoint inhibitor‑related enterocolitis in the second quarter of this year. This serious condition affects up to 50% of immune checkpoint‑treated cancer patients, with rates varying based on cancer drug and treatment regimen, and represents a sizable therapeutic and commercial opportunity." President and CEO Eric Shaff noted, "We have made significant progress advancing SER‑155 as a novel live biotherapeutic candidate designed to prevent life‑threatening bloodstream infections in allo‑HSCT recipients." Co‑CEOs Thomas DesRosier and Marella Thorell added, "We are progressing start‑up activities for our Breakthrough Therapy designated SER‑155 live biotherapeutic program and are pleased with the further constructive feedback from the FDA, including on key parameters such as study size, primary endpoint, and interim analysis plan, that we expect will allow us to finalize the Phase 2 study protocol."
Headwinds for the company include the need for additional capital to support its clinical programs and recent workforce reductions aimed at extending the cash runway. Tailwinds are the progress on SER‑155 and SER‑603, which could open significant therapeutic and commercial opportunities if the clinical data are positive. The company’s guidance that it can fund operations through Q3 2026 reflects cautious optimism about its financial position while acknowledging the ongoing need for financing to sustain its pipeline.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.